KM Research Hub
← 返回论文库
部分完成 入排:符合 图源:可得 入排置信度 0.98

The prognostic and predictive value of the luminal-like subtype in hormone receptor-positive breast cancer: an analysis of the DATA trial.

S W M Lammers, S M E Geurts, K E P E Hermans, L F S Kooreman, A C P Swinkels, C H Smorenburg, M J C van der Sangen, J R Kroep, A H Honkoop, F W P J van den Berkmortel, W K de Roos, S C Linn, A L T Imholz, I J H Vriens, V C G Tjan-Heijnen, Dutch Breast Cancer Research Group (BOOG) for the DATA investigators

ESMO Open 10(2) 104154

PMID39921934
PMCIDPMC11850755
DOI10.1016/j.esmoop.2025.104154
发表日期2025-02-08
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:图像复核确认至少一个 KM 面板含可见 No. at risk 表。
摘要

摘要

BACKGROUND: This study determines the prognostic value of the luminal-like subtype in patients with hormone receptor-positive breast cancer and explores whether the efficacy of extended anastrozole therapy differs between patients with luminal A-like versus luminal B-like tumours. MATERIALS AND METHODS: The phase III DATA study (NCT00301457) examined the efficacy of 6 versus 3 years of anastrozole in postmenopausal women with early-stage hormone receptor-positive breast cancer who had received 2-3 years of tamoxifen. Patients with available formalin-fixed paraffin-embedded tissue blocks were identified and classified by immunohistochemical luminal-like subtype. Distant recurrence (DR) and breast cancer-specific mortality (BCSM) were compared by luminal-like subtype and treatment arm using competing risk methods. RESULTS: This study included 788 patients: 491 had a luminal A-like tumour and 297 had a luminal B-like tumour. The median follow-up time was 13.1 years. Patients with luminal B-like tumours experienced a higher risk of DR [subdistribution hazard ratio (sHR) 1.44, 95% confidence interval (CI) 1.03-2.01, P = 0.03] and BCSM (sHR 1.68, 95% CI 1.15-2.45, P = 0.008) than patients with luminal A-like tumours. The efficacy of extended anastrozole therapy differed between patients with luminal A-like tumours (DR: sHR 0.51, 95% CI 0.30-0.88, P = 0.02; BCSM: sHR 0.39, 95% CI 0.19-0.82, P = 0.01) and patients with luminal B-like tumours (DR: sHR 2.09, 95% CI 0.96-4.53, P = 0.06; BCSM: sHR 2.36, 95% CI 0.80-7.00, P = 0.12) (P-interaction = 0.03 and P-interaction = 0.06, respectively). CONCLUSION: In patients with hormone receptor-positive breast cancer, the luminal B-like subtype was associated with a significantly worse prognosis when compared with the luminal A-like subtype. Extended anastrozole therapy halved the risk of DR and BCSM in patients with luminal A-like tumours, whereas no effect was seen in patients with luminal B-like tumours.

KM 提取结果

1 个 Figure · 4 个 KM 面板

进入结果中心
KM Figure4 个面板

Figure 1

Distant recurrence (DR) (A), breast cancer-specific mortality (BCSM) (B), disease-free survival (DFS) (C), and overall survival (OS) (D) according to luminal-like subtype. CI, confidence interval.

A

Distant recurrence

Figure 1 · Panel A

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel A 是同一 Figure 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
B

Breast cancer-specific mortality

Figure 1 · Panel B

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel B 是同一 Figure 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
C

Disease-free survival

Figure 1 · Panel C

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel C 是同一 Figure 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
D

Overall survival

Figure 1 · Panel D

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel D 是同一 Figure 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 2Adapted distant recurrence (aDR) in patients with luminal A-like tumours (A) and patients with luminal B-like tumours (B) and adapted breast cancer-specific mortality (aBCSM) in patients with luminal A-like tumours (C) and patients with luminal B-like tumours (D) according to assigned treatment from 3 years after randomisation onwards. CI, confidence interval.
非 KM Figure
Figure 3Multivariable analyses of adapted distant recurrence, adapted breast cancer-specific mortality, adapted disease-free survival, and adapted overall survival evaluating the efficacy of 6 versus 3 years of anastrozole from 3 years after randomisation onwards, stratified by luminal-like subtype. CI, confidence interval; s(HR), subdistribution hazard ratio. a Analyses were adjusted for age, tumour status, nodal status, histology, and prior chemotherapy.
非 KM Figure